Most Liquid Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1IMTXW immatics biotechnologies GmbH
178.39 M
(0.22)
 10.72 
(2.33)
2GRAL GRAIL, LLC
139.75 M
 0.11 
 3.81 
 0.41 
3LENZ LENZ Therapeutics
138.69 M
 0.18 
 4.65 
 0.85 
4GPCR Structure Therapeutics American
136.28 M
(0.03)
 4.24 
(0.11)
5BCAX Bicara Therapeutics Common
129.03 M
 0.07 
 5.92 
 0.44 
6AVBP ArriVent BioPharma, Common
128.72 M
 0.05 
 3.74 
 0.21 
7NGNE Neurogene
109.68 M
 0.01 
 11.65 
 0.16 
8APGE Apogee Therapeutics, Common
108.08 M
(0.04)
 3.47 
(0.16)
9ZURA Zura Bio Limited
104.8 M
(0.07)
 5.12 
(0.37)
10GMAB Genmab AS
21.61 B
(0.28)
 1.52 
(0.42)
11ABBV AbbVie Inc
11.88 B
(0.04)
 2.09 
(0.08)
12GILD Gilead Sciences
6.14 B
 0.19 
 1.42 
 0.27 
13GLPG Galapagos NV ADR
4.43 B
(0.01)
 2.28 
(0.03)
14CRSP Crispr Therapeutics AG
2.07 B
 0.05 
 2.92 
 0.14 
15EXEL Exelixis
1.53 B
 0.22 
 2.40 
 0.54 
16DNA Ginkgo Bioworks Holdings
1.32 B
 0.09 
 5.67 
 0.50 
17NVAX Novavax
1.28 B
(0.08)
 5.59 
(0.42)
18CNTB Connect Biopharma Holdings
1.28 B
(0.10)
 5.52 
(0.54)
19ZLAB Zai Lab
1.26 B
 0.15 
 4.11 
 0.63 
20BNR Burning Rock Biotech
1.15 B
 0.04 
 8.71 
 0.39 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).